Tags

Type your tag names separated by a space and hit enter

Risk of metabolic syndrome in postmenopausal breast cancer survivors.
Menopause. 2013 Apr; 20(4):448-54.M

Abstract

OBJECTIVE

The aim of this study was to assess the risk of metabolic syndrome (MetS) in postmenopausal breast cancer survivors as compared with postmenopausal women without breast cancer.

METHODS

In this cross-sectional study, 104 postmenopausal breast cancer survivors were compared with 208 postmenopausal women (controls) attending a university hospital. Eligibility criteria included the following: amenorrhea longer than 12 months and aged 45 years or older, treated for breast cancer, and metastasis-free for at least 5 years. The control group consisted of women with amenorrhea longer than 12 months and aged 45 years or older and without breast cancer, matched by age and menopause status (in a proportion of 1:2 as sample calculation). Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, and C-reactive protein, were measured. Women showing three or more diagnostic criteria were diagnosed as having MetS: waist circumference of 88 cm or larger, blood pressure of 130/85 mm Hg or higher, triglycerides level of 150 mg/dL or higher, high-density lipoprotein cholesterol level lower than 50 mg/dL, and glucose level of 100 mg/dL or higher. For statistical analysis, Student's t test, χ2 test, and logistic regression (odds ratio [OR]) were used.

RESULTS

The mean (SD) age of breast cancer survivors was 60.6 (8.6) years, with a mean (SD) follow-up of 9.4 (4.4) years. A higher percentage of breast cancer survivors (46.2%) were obese as compared with controls (32.7%; P < 0.05), and a smaller percentage showed optimal values for low-density lipoprotein cholesterol, glucose, and C-reactive protein versus controls (P < 0.05). MetS was diagnosed in 50% of breast cancer survivors and in 37.5% of control group women (P < 0.05). Among the MetS diagnostic criteria, the most prevalent was abdominal obesity (waist circumference >88 cm), affecting 62.5% and 67.8% of the participants, respectively. In the control group, breast cancer survivors had a higher risk for MetS (OR, 1.66; 95% CI, 1.04-2.68), dysglycemia (OR, 1.05; 95% CI, 1.09-3.03), and hypertension (OR, 1.71; 95% CI, 1.02-2.89).

CONCLUSIONS

Postmenopausal breast cancer survivors present a higher risk of developing MetS as compared with women without breast cancer.

Authors+Show Affiliations

Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University, São Paulo, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23149866

Citation

Buttros, Daniel de Araújo Brito, et al. "Risk of Metabolic Syndrome in Postmenopausal Breast Cancer Survivors." Menopause (New York, N.Y.), vol. 20, no. 4, 2013, pp. 448-54.
Buttros Dde A, Nahas EA, Vespoli Hde L, et al. Risk of metabolic syndrome in postmenopausal breast cancer survivors. Menopause. 2013;20(4):448-54.
Buttros, D. d. e. . A., Nahas, E. A., Vespoli, H. d. e. . L., Uemura, G., de Almeida, B. d. a. . R., & Nahas-Neto, J. (2013). Risk of metabolic syndrome in postmenopausal breast cancer survivors. Menopause (New York, N.Y.), 20(4), 448-54. https://doi.org/10.1097/gme.0b013e318272bd4a
Buttros Dde A, et al. Risk of Metabolic Syndrome in Postmenopausal Breast Cancer Survivors. Menopause. 2013;20(4):448-54. PubMed PMID: 23149866.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of metabolic syndrome in postmenopausal breast cancer survivors. AU - Buttros,Daniel de Araújo Brito, AU - Nahas,Eliana Aguiar Petri, AU - Vespoli,Heloísa De Luca, AU - Uemura,Gilberto, AU - de Almeida,Bruno da Rosa, AU - Nahas-Neto,Jorge, PY - 2012/11/15/entrez PY - 2012/11/15/pubmed PY - 2014/3/7/medline SP - 448 EP - 54 JF - Menopause (New York, N.Y.) JO - Menopause VL - 20 IS - 4 N2 - OBJECTIVE: The aim of this study was to assess the risk of metabolic syndrome (MetS) in postmenopausal breast cancer survivors as compared with postmenopausal women without breast cancer. METHODS: In this cross-sectional study, 104 postmenopausal breast cancer survivors were compared with 208 postmenopausal women (controls) attending a university hospital. Eligibility criteria included the following: amenorrhea longer than 12 months and aged 45 years or older, treated for breast cancer, and metastasis-free for at least 5 years. The control group consisted of women with amenorrhea longer than 12 months and aged 45 years or older and without breast cancer, matched by age and menopause status (in a proportion of 1:2 as sample calculation). Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, and C-reactive protein, were measured. Women showing three or more diagnostic criteria were diagnosed as having MetS: waist circumference of 88 cm or larger, blood pressure of 130/85 mm Hg or higher, triglycerides level of 150 mg/dL or higher, high-density lipoprotein cholesterol level lower than 50 mg/dL, and glucose level of 100 mg/dL or higher. For statistical analysis, Student's t test, χ2 test, and logistic regression (odds ratio [OR]) were used. RESULTS: The mean (SD) age of breast cancer survivors was 60.6 (8.6) years, with a mean (SD) follow-up of 9.4 (4.4) years. A higher percentage of breast cancer survivors (46.2%) were obese as compared with controls (32.7%; P < 0.05), and a smaller percentage showed optimal values for low-density lipoprotein cholesterol, glucose, and C-reactive protein versus controls (P < 0.05). MetS was diagnosed in 50% of breast cancer survivors and in 37.5% of control group women (P < 0.05). Among the MetS diagnostic criteria, the most prevalent was abdominal obesity (waist circumference >88 cm), affecting 62.5% and 67.8% of the participants, respectively. In the control group, breast cancer survivors had a higher risk for MetS (OR, 1.66; 95% CI, 1.04-2.68), dysglycemia (OR, 1.05; 95% CI, 1.09-3.03), and hypertension (OR, 1.71; 95% CI, 1.02-2.89). CONCLUSIONS: Postmenopausal breast cancer survivors present a higher risk of developing MetS as compared with women without breast cancer. SN - 1530-0374 UR - https://www.unboundmedicine.com/medline/citation/23149866/Risk_of_metabolic_syndrome_in_postmenopausal_breast_cancer_survivors_ L2 - https://doi.org/10.1097/gme.0b013e318272bd4a DB - PRIME DP - Unbound Medicine ER -